We are live on
!
Find out more
GFM
GF Fund Management Portfolio holdings
AUM
$5.98B
1-Year Est. Return
80.99%
This Fund
S&P 500
This Quarter
Est. Return
+7.58%
1 Year Est. Return
+80.99%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$4.62B
AUM Growth
–
Cap. Flow
+$4.56B
Cap. Flow
% of AUM
98.7%
Top 10 Holdings %
Top 10 Hldgs %
48.03%
Holding
637
New
637
Increased
–
Reduced
–
Closed
–
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$400M |
| 2 |
Apple
AAPL
|
+$352M |
| 3 |
Microsoft
MSFT
|
+$326M |
| 4 |
Amazon
AMZN
|
+$218M |
| 5 |
Meta Platforms (Facebook)
META
|
+$195M |
Top Sells
No sells this quarter
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 45.41% |
| 2 | Consumer Discretionary | 17.29% |
| 3 | Communication Services | 14.35% |
| 4 | Healthcare | 6.6% |
| 5 | Consumer Staples | 4.55% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
376
Twist Bioscience
TWST
$5.32B
| $57.9K | ﹤0.01% |
+1,246
| New | +$56.3K |
|
377
Vericel Corp
VCEL
$2.38B
| $56.9K | ﹤0.01% |
+1,036
| New | +$52.4K |
|
378
Douglas Emmett
DEI
$2.05B
| $56.5K | ﹤0.01% |
+3,042
| New | +$56.7K |
|
|
SWTX
379
DELISTED
SpringWorks Therapeutics
SWTX
| $56.4K | ﹤0.01% |
+1,562
| New | +$54.6K |
|
380
Vera Therapeutics
VERA
$2.33B
| $56.2K | ﹤0.01% |
+1,330
| New | +$58.9K |
|
381
Legend Biotech
LEGN
$3.65B
| $55.8K | ﹤0.01% |
+1,715
| New | +$71K |
|
382
Kymera Therapeutics
KYMR
$8.66B
| $54.7K | ﹤0.01% |
+1,360
| New | +$61.4K |
|
383
Broadstone Net Lease
BNL
$4.25B
| $54.3K | ﹤0.01% |
+3,426
| New | +$59.7K |
|
384
Recursion Pharmaceuticals
RXRX
$1.58B
| $54.2K | ﹤0.01% |
+8,016
| New | +$53.9K |
|
385
Park Hotels & Resorts
PK
$3.08B
| $53.4K | ﹤0.01% |
+3,796
| New | +$55.7K |
|
386
Edgewise Therapeutics
EWTX
$4.28B
| $53.1K | ﹤0.01% |
+1,988
| New | +$63.3K |
|
387
Amneal Pharmaceuticals
AMRX
$6.1B
| $51.5K | ﹤0.01% |
+6,506
| New | +$54.6K |
|
388
Dyne Therapeutics
DYN
$4.68B
| $50.3K | ﹤0.01% |
+2,137
| New | +$63.2K |
|
389
NewAmsterdam Pharma
NAMS
$3.26B
| $49.9K | ﹤0.01% |
+1,940
| New | +$41.2K |
|
|
NSA
390
DELISTED
National Storage Affiliates Trust
NSA
| $49.7K | ﹤0.01% |
+1,311
| New | +$56.2K |
|
391
Arrowhead Research
ARWR
$12.1B
| $49.1K | ﹤0.01% |
+2,613
| New | +$53.8K |
|
392
Protagonist Therapeutics
PTGX
$8.55B
| $48.3K | ﹤0.01% |
+1,251
| New | +$54.5K |
|
393
Urban Edge Properties
UE
$2.9B
| $47.4K | ﹤0.01% |
+2,205
| New | +$49K |
|
394
Iovance Biotherapeutics
IOVA
$2.04B
| $47.4K | ﹤0.01% |
+6,400
| New | +$59.3K |
|
395
IDEAYA Biosciences
IDYA
$3.43B
| $46.6K | ﹤0.01% |
+1,815
| New | +$51.4K |
|
396
Acadia Realty Trust
AKR
$3.11B
| $46.2K | ﹤0.01% |
+1,914
| New | +$46.9K |
|
397
Four Corners Property Trust
FCPT
$2.89B
| $45.7K | ﹤0.01% |
+1,684
| New | +$48K |
|
398
Geron
GERN
$898M
| $44.9K | ﹤0.01% |
+12,693
| New | +$50.7K |
|
399
Tarsus Pharmaceuticals
TARS
$2.55B
| $44.5K | ﹤0.01% |
+803
| New | +$36.5K |
|
400
LXP Industrial Trust
LXP
$3.52B
| $43.4K | ﹤0.01% |
+1,070
| New | +$49.6K |
|
Similar funds
CM
BP
AAM
CAG
WHRC
RCG
AL
CGPCS
GF Fund Management's Q4 2024 Portfolio in Review
Q4 2024 is the first quarter with a 13F filing on record for GF Fund Management, which disclosed 637 positions worth $4.62B. Its ten largest holdings account for 48% of the portfolio.
Its largest position is NVIDIA: 2,904,119 shares worth $390M.
By sector, the portfolio is most concentrated in Technology at 45% of assets, followed by Consumer Discretionary and Communication Services.
- GF Fund Management's largest Q4 2024 buy was NVIDIA: 2,904,119 shares worth $390M.
- GF Fund Management's ten largest holdings make up 48% of its $4.62B portfolio in Q4 2024.
- GF Fund Management disclosed 637 positions in Q4 2024, its first 13F filing on record.
Based on GF Fund Management's 13F filing for Q4 2024, filed 19 Feb 2025.